# NAD+ Research: Mechanism, Decline With Age, and What the Trials Measured

> NAD+ research, step by step: the salvage pathway, the age-related decline driven by CD38, and what human and rodent studies measured — blood NAD+ elevation, muscle insulin sensitivity, blood pressure. Cited to source.

How the coenzyme is rebuilt, why it declines with age, and what specific human and rodent studies actually found.

## The short version

This page follows NAD+ research as a sequence. The cell rebuilds NAD+ (the energy-handling helper molecule from the home page) mainly through a recycling loop called the salvage pathway, run by an enzyme named NAMPT. As the body ages, tissue NAD+ drops — in part because another enzyme, CD38, ramps up and eats into the supply. Researchers have measured what happens when you refill the pool using oral precursors (the building blocks NMN and NR): blood NAD+ reliably rises, and in some trials muscle and cardiovascular measures shifted too. A 2025 review is candid that the hard, long-term human benefits are still unproven. The cited steps follow.

## How the cell rebuilds NAD+: the salvage pathway

Mammals make NAD+ three ways, but the dominant route is the salvage pathway, which recycles nicotinamide back into NAD+ through the rate-limiting enzyme NAMPT (nicotinamide phosphoribosyltransferase) and then NMNAT [5]. "Rate-limiting" is the key phrase: NAMPT sets the ceiling on how fast the cell can rebuild the coenzyme, so its abundance largely dictates the size of the NAD+ pool. NAMPT activity is induced by exercise and follows a circadian rhythm, which is one reason NAD+ levels swing across the day [5].

The other two routes feed the same pool. De novo synthesis builds NAD+ from the amino acid tryptophan; the Preiss-Handler pathway builds it from nicotinic acid (niacin) [5]. NR enters through a fourth shortcut: NRK kinases convert it to NMN, bypassing the Preiss-Handler step entirely [5]. The reason all of this matters for supplements is simple — these pathways are how a swallowed precursor becomes usable NAD+, and they are why intact oral NAD+ is largely beside the point.

This is also why the literature treats the four precursors as related but not identical. Niacin and nicotinamide are the original vitamin-B3 forms; NR and NMN are the newer, more direct entries. Each lands at a different point on the map — niacin at Preiss-Handler, nicotinamide at the salvage entry, NR at the NRK shortcut, NMN one step from the finish — and that routing partly explains why their human readouts differ. The molecule a cell ends up using is the same NAD+; the road it took to get there is not.

## NAD+ Decline With Age: CD38, Sirtuins and PARPs

The story of NAD+ and aging turns on a simple imbalance: the coenzyme is not just synthesized, it is spent. Three families of enzymes consume it: sirtuins (SIRT1–SIRT7, NAD+-dependent deacylases that regulate metabolism, stress resistance, and DNA repair), PARP1 (a DNA-repair enzyme that draws heavily on NAD+ when DNA is damaged), and CD38/CD157 (NAD-consuming surface enzymes) [5]. They compete for one shared pool.

CD38 is the pivotal character in the aging story. In mice, CD38 is the principal NAD+-consuming enzyme whose activity rises with age, driving the fall in tissue NAD+; CD38-knockout mice are protected against that decline, preserving NAD+ levels and SIRT3 activity and maintaining mitochondrial function with age [2]. SIRT3 itself — a mitochondrial NAD+-dependent deacylase — regulates mitochondrial biogenesis through the AMPK–PGC1α axis, and its loss impairs ATP production and antioxidant defense [9].

Reviews frame this declining NAD+ as a candidate unifying feature of aging. One foundational review links the age-related drop to metabolic dysfunction and disease susceptibility across yeast, worms, mice, and humans [5]; another proposes NAD+ depletion as a bridging mechanism between aging and age-related diseases including cancer [14]. The NAD+/NADH and NADP+/NADPH redox couples are positioned in the broader literature as fundamental regulators of energy metabolism, calcium signaling, antioxidation, and cell death [13].

## What NAD+ Research Has Measured

Here the evidence gets concrete — and worth stating plainly as NAD+ benefits the trials actually recorded, not health claims. The most reproducible human finding is that oral precursors raise whole-blood NAD+ in a dose-dependent way. NR did so by 22%, 51%, and 142% at 100, 300, and 1000 mg/day over eight weeks, without raising LDL cholesterol or disrupting one-carbon metabolism [4]. NMN did so across 300–900 mg/day over 60 days in a multicenter trial, which also reported improved walking distance and no rise in a biological-age measure [3].

Functional endpoints are more mixed but include real signals. Ten weeks of oral NMN at 250 mg/day significantly increased muscle insulin sensitivity and remodeled insulin signaling in prediabetic, postmenopausal women — though body composition and HbA1c did not change [1]. In rodents, NMN restored NAD+ in liver and skeletal muscle and improved glucose tolerance in diet- and age-induced diabetes models, partly through SIRT1 [7]. The [cardiometabolic studies](/nad-and-heart-health) — heart failure, blood pressure, arterial stiffness — get their own page.

The honest counterweight: a 2025 Nature Metabolism review of human NAD+-precursor evidence in aging concluded that trials have shown limited efficacy for hard clinical endpoints, that age-related NAD+ decline has been confirmed in only a limited number of human studies, and that tissue-specific NAD+ data remain sparse [15]. Blood NAD+ elevation is consistent; translation to clinical outcomes is not.

## NAD+ beyond metabolism: the research edges

NAD+ metabolism reaches into fields outside supplementation, and the cited record here is preclinical. In glaucoma-prone mice, retinal NAD+ declined with age and oral nicotinamide (vitamin B3) was protective, with 93% of eyes not developing glaucoma at the highest dose tested [12]. The mechanism proposed was that the age-related NAD+ drop left retinal neurons metabolically vulnerable, and refilling the pool — by supplement or by gene therapy targeting Nmnat1 — restored their resilience [12].

In oncology, the relationship is dual-edged. BRAF-inhibitor-resistant melanoma cells upregulated the NAD+ biosynthetic enzyme NAMPT, and a NAMPT inhibitor depleted NAD+ and ATP and improved survival in xenograft-bearing mice [11] — a reminder that proliferating cells also depend on NAD+, which is why a theoretical caution exists around boosting it in cancer populations. One review goes further and frames NAD+ depletion as a candidate bridge between aging and cancer, with the same coenzyme playing protective and permissive roles depending on context [14].

These are mechanistic and animal findings, not human treatment evidence. They are included to map where NAD+ research is active — and to make the point that "more NAD+" is not uniformly and unconditionally good — not to imply that any precursor treats eye disease or cancer.

## Does NAD make you look younger?

No trial shows NAD+ or its precursors reverse visible aging. Tissue NAD+ declines with age, and rodent studies link repletion to improved physiology, but human reviews (2025) conclude efficacy for hard age-related endpoints remains preliminary [15][2]. There is no controlled evidence for a cosmetic anti-aging effect.

---

A step-by-step explainer of the NAD+ literature — the coenzyme drawn apart from the precursors NMN and NR that rebuild it, each finding wired to its study and each gap left openly marked; no clinic behind the diagram and nothing here infused, dispensed, or sold.